Paul Conyngham uses AI tools to help design a personalized mRNA cancer vaccine for Rosie, his rescue dog, who has aggressive mast cell cancer. Five months later, Gamgee launches based on Rosie’s case with a $4 million seed round led by Founders Fund.
Paul Conyngham's startup Gamgee launches in Y Combinator's Summer 2026 batch with a personalized cancer-vaccine approach for dogs. The company sequences a dog's tumor and healthy DNA, uses computational tools to identify driver mutations, and manufactures an mRNA vaccine designed to teach that dog's immune system what to attack.
Gamgee launches to develop personalized mRNA cancer vaccines for dogs, backed by a $4 million seed round led by Founders Fund. The round also includes Celine Halioua, Steve Eidelman, Arash Ferdowsi, and Gokul Rajaram; the company describes its origins as one dog's fight.
Gamgee, founded by Paul Conyngham, joins Y Combinator’s Summer 2026 batch and runs clinical trials in Australia while accepting cases globally. The company follows the viral story of Conyngham’s dog Rosie and her personalized mRNA cancer vaccine, which preceded Gamgee’s launch as a company.
